Effects of two different doses of leuprolide acetate depot on uterine cavity area in patients with uterine leiomyomata.
OBJECTIVE
To compare the effects of two different doses of a monthly depot injection of a GnRH agonist (GnRH-a) on uterine cavity area in patients with uterine leiomyomata.


METHODS
Prospective, randomized study.


METHODS
Hospital department of obstetrics and gynecology.


METHODS
Thirty-six premenopausal women, 25 to 52 years of age, with uterine leiomyomata.


METHODS
Leuprolide acetate (LA) depot, 1.88 or 3.75 mg, was administered SC every 4 weeks for 24 weeks.


METHODS
Uterine cavity area before and after treatment was assessed by hysterosalpingography.


RESULTS
The 1.88- and 3.75-mg LA depots significantly reduced uterine cavity area by 40.8% and 40.2%, respectively. No significant difference was observed between the two groups.


CONCLUSIONS
Monthly injection of 1.88 or 3.75 mg LA depots appears to reduce uterine cavity area to a similar extent in patients with uterine leiomyomata.
Watanabe
Y
Y
Department of Obstetrics and Gynecology, Hamanomachi Hospital, Fukuoka, Japan.
Nakamura
G
G
D000328:Adult; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D018231:Leiomyomatosis / Q000188:drug therapy* / Q000473:pathology; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014599:Uterus / Q000473:pathology*
D003692:Delayed-Action Preparations; D016729:Leuprolide